Thus, having the ability to specifically target electrically silent KCNF1 in lung cancer could provide the long-awaited significant advantage of not affecting normal and physiologically expressed K+ channels, but more precisely targeting cancer cells. The gene discussed is KCNF1; the disease is lung carcinoma.